Advances in Therapy

, Volume 22, Issue 1, pp 25–31 | Cite as

Use of sibutramine an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: A placebo-controlled study

  • W. Milano
  • C. Petrella
  • A. Casella
  • A. Capasso
  • S. Carrino
  • L. Milano


Binge-eating disorder, which is characterized by repeated episodes of uncontrolled eating, is common in obese patients and is often accompanied by comorbid psychiatric disorders, especially depression. In previous studies, selective serotonin reuptake inhibitors have demonstrated efficacy in reducing the frequency of binge eating and addressing comorbid psychiatric disorders, but they have not shown the ability to promote weight loss. Sibutramine, a new serotonin and norepinephrine reuptake inhibitor, has been shown in short- and long-term studies to be effective in promoting and maintaining weight loss in obese patients who have binge-eating disorder. In this randomized, double-blind, placebo-controlled study, the efficacy, safety, and tolerability of sibutramine were evaluated in the treatment of binge-eating disorder in obese patients. Twenty patients were randomly assigned in equal numbers to receive either sibutramine 10 mg/day or placebo for 12 weeks. Assessments were made at baseline and every 2 weeks throughout the study. Binge frequency, defined as the number of days during the previous week that included binge-eating episodes, was the primary outcome measure. By the end of the study, the binge frequency among patients given sibutramine was significantly lower than that among those given placebo. The main adverse events in the sibutramine group were dry mouth and constipation. The findings suggest sibutramine is an effective medication in the treatment of binge-eating disorders and is well tolerated. In addition, it addresses the 3 main goals in the treatment of binge-eating disorder: reducing the frequency of binge eating, promoting and maintaining weight loss, and treating the comorbid psychiatric conditions.


binge-eating disorder sibutramine obesity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Muscettola G, Casiello M. Psicofarmacologia dei disordini del comportamento alimentare. In: Bellantuono C, Balestrino M, eds.Gli psicofarmaci: farmacologia e terapia. Rome, Italy: Il Pensiero Scientifico Editore; 1997:13–24.Google Scholar
  2. 2.
    American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.Google Scholar
  3. 3.
    Walsh T, Devlin M. Eating disorders: progress and problems.Science. 1998;280:1387–1390.PubMedCrossRefGoogle Scholar
  4. 4.
    Cuzzolaro M, Magnani M. Obesità e disturbi del comportamento alimentare. In: Borsello O, ed.Obesità. Milan, Italy: Editrice Kurtis;1998:16–22.Google Scholar
  5. 5.
    Bellodi L, Brambilla F. Eating Disorders and Obsessive Compulsive Disorder: An Etiopathogenetic Link? Torino, Italy: Centro Scientifio Editore. 1999.Google Scholar
  6. 6.
    Walsh BT. Binge eating in bulimia nervosa. In: Fairburn CG, Wilson GT, eds.Binge Eating: Nature, Assessment and Treatment. New York, NY: Guilford Press;1993:60–51.Google Scholar
  7. 7.
    Stunkard AJ. Some perspectives on human obesity: its causes.Bull N Y Acad Med. 1988;64:902–911.PubMedGoogle Scholar
  8. 8.
    Stunkard AJ. Binge eating disorder and the treatment of obesity.Obese Res. 1991;2:279–283.Google Scholar
  9. 9.
    Yanoski SZ, Nelson JE, Dubbert B, Spitzer RL. Binge eating disorder is associated with psychiatric comorbidity in the obese.Am J Psychiatry. 1993;150:1472–1479.Google Scholar
  10. 10.
    Stuart RR. Behavioural control of overeating.Behav Res Ther. 1967;5:357–364.CrossRefGoogle Scholar
  11. 11.
    Ricca V, Mannucci E, Di Bernardo M. Disturbo da Alimentazione Incontrollata [Binge Eating Disorder].Giornale Italiano di Psicopatologia. 1998;2:223–239.Google Scholar
  12. 12.
    Brewerton TD. Toward a unified theory of serotonin dysregulation in eating and related disorders.Psychoneuroendocrinology. 1995;20:561–590.PubMedCrossRefGoogle Scholar
  13. 13.
    Ramacciotti C. Terapia farmacologica della bulimia nervosa e del BED. In: Cuzzolaro M, ed.Terapia farmacologica dei disturbi del comportamento alimentare. Editrice Kurtis; 2000:30–35.Google Scholar
  14. 14.
    Leibowitz SF, Shor-Posner G. Brain serotonin and eating behavior.Appetite. 1986;7(suppl):1–14.PubMedGoogle Scholar
  15. 15.
    Jimerson DC, Wolfe BE, Metzger ED, Finkelstein DM, Cooper TB, Levine JM. Decreased serotonin function in bulimia nervosa.Arch Gen Psychiatry. 1997;54:529–534.PubMedGoogle Scholar
  16. 16.
    Muller E, Brambilla F.Disordini del comportamento alimentare. Milan, Italy: Pythagora Press; 1997.Google Scholar
  17. 17.
    Devane CL. Comparative safety and tolerability of selective serotonin reuptake inhibitors.Human Psychopharmacol. 1995;10(suppl 3):S185-S193.CrossRefGoogle Scholar
  18. 18.
    American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders (revision). American Psychiatric Association Work Group on Eating Disorders.Am J Psychiatry. 2000;157(suppl 1):1–39.Google Scholar
  19. 19.
    Kay WH. Serotonin regulation in bulimia. In: Hudson J, Pope H Jr, eds.The Psychobiology of Bulimia. Washington, DC: APA Press; 1987.Google Scholar
  20. 20.
    Buckett WR, Thomas PG, Luscombe GP. The pharmacology of sibutramine hydrochloride, a new antidepressant which induces rapid noradrenergic down-regulation.Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:575–584.PubMedCrossRefGoogle Scholar
  21. 21.
    Stricker-Krongrad A, Souquet AM, Burlet C. Effects of sibutramine on feeding behaviour in dietary-induced obesity role of dietary constituents.Int J Obes. 1995;19:P399.Google Scholar
  22. 22.
    Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss.Obes Res. 1999;7:189–198.PubMedGoogle Scholar
  23. 23.
    Cole JO, Kaiser PE, DeHaan HA. Sibutramine hydrochloride: evaluation of abuse potential.Obes Res. 1991;1(suppl 2):145.Google Scholar
  24. 24.
    Weintraub M, Rubio A, Golik A, Byrne L, Scheinbum ML. Sibutramine in weight control: a dose-ranging efficacy study.Clin Pharmacol Ther. 1991;50:330–337.PubMedCrossRefGoogle Scholar
  25. 25.
    Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.Obes Rev. 2000;1:127–139.PubMedCrossRefGoogle Scholar
  26. 26.
    Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation.Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:575–584.PubMedCrossRefGoogle Scholar
  27. 27.
    Gundlah C, Martin KF, Heal DJ, Auerbach SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.J Pharmacol Exp Ther. 1997; 283:581–591.PubMedGoogle Scholar
  28. 28.
    Stricker-Krograd A, Burlet C, Souqurt AM. Effects of sibutramine on feeding behaviour in dietary-induced obesity: a role of dietary components.Int J Obes. 1995;19(suppl 12):145.Google Scholar
  29. 29.
    Kaiser PE, Hinson JL. Sibutramine: dose response and plasma metabolic concentrations in weight loss.J Clin Pharmacol. 1994;34:1019.Google Scholar
  30. 30.
    Van Gaal LF, Wauters MA De, Leew IH. Anti-obesity drugs, what does sibutramine offer? An analysis of its potential contribution of obesity treatment.Exp Clin Endocrinol Diabetes. 1998;106:35–40.PubMedCrossRefGoogle Scholar

Copyright information

© Health Communications Inc 2005

Authors and Affiliations

  • W. Milano
    • 1
  • C. Petrella
    • 1
  • A. Casella
    • 2
  • A. Capasso
    • 2
  • S. Carrino
    • 3
  • L. Milano
    • 4
  1. 1.Mental Health Operations UnitNapoli 1Italy
  2. 2.Dipartimento di Scienze FarmaceuticheUniversità di SalernoFisciano SalernoItalia
  3. 3.Office of EndocrinologyNapoli 1Italy
  4. 4.Fatebenefratelli HospitalBeneventoItaly

Personalised recommendations